A Review of Triple-Negative Breast Cancer (Q37776143)

23 August 2017

1 reference

title

A review of triple-negative breast cancer (English)

1 reference

23 August 2017

A Review of Triple-Negative Breast Cancer (English)

1 reference

DOI

https://api.crossref.org/works/10.1177/107327481001700305

11 June 2024

1 reference

Roohi Ismail-Khan

1 reference

23 August 2017

Marilyn M. Bui

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20664514

11 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20664514

11 June 2024

publication date

1 July 2010

1 reference

full work available at URL

23 August 2017

http://journals.sagepub.com/doi/pdf/10.1177/107327481001700305

1 reference

DOI

https://api.crossref.org/works/10.1177/107327481001700305

11 June 2024

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

173-176

1 reference

23 August 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Basal-like breast cancer: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Prognostic markers in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Basal carcinoma of the breast revisited: an old entity with new interpretations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

The basic pathology of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481001700305

Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/107327481001700305

High-dose chemotherapy for triple negative breast cancer

11 June 2024

1 reference

https://api.crossref.org/works/10.1177/107327481001700305

11 June 2024

Identifiers

DOI

0 references

1 reference